Immunotherapy plus radiation before lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether giving a combination of the immunotherapy drug tislelizumab and chest radiation before surgery can improve outcomes for people with early-stage, operable lung cancer. The goal is to find out if this approach helps shrink the tumor and makes surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have not had any prior cancer treatment for this lung cancer.
- Your cancer is stage IB, II, or IIIA (doctors believe it can be surgically removed).
- You are between 18 and 70 years old.
- You are healthy enough to have surgery (adequate lung function and overall health).
- You are willing to provide a tumor sample for PD-L1 testing.
- If you could become pregnant, you must agree to use effective birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and chemotherapy) given before and after surgery to treat stage II-IIIB non-small cell lung cancer. The goal is to see if this approach can improve outcomes for patients whose cancer can be removed surgically.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
Hear when a new Resectable NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.